CBR Division Defence Science and Technology Laboratory Porton Down, Salisbury, United Kingdom.
Lydia Becker Institute for Immunology and Inflammation, Wellcome Trust Centre for Cell-Matrix Research, Faculty of Biology, Medicine and Health, Manchester Academic Health Sciences Centre, University of Manchester, Manchester, United Kingdom.
Microbiol Spectr. 2023 Jun 15;11(3):e0401622. doi: 10.1128/spectrum.04016-22. Epub 2023 May 18.
Antimicrobial resistance continues to be a global issue. Pathogens, such as Burkholderia pseudomallei, have evolved mechanisms to efflux certain antibiotics and manipulate the host response. New treatment strategies are therefore required, such as a layered defense approach. Here, we demonstrate, using biosafety level 2 (BSL-2) and BSL-3 murine models, that combining the antibiotic doxycycline with an immunomodulatory drug that targets the CD200 axis is superior to antibiotic treatment in combination with an isotype control. CD200-Fc treatment alone significantly reduces bacterial burden in lung tissue in both the BSL-2 and BSL-3 models. When CD200-Fc treatment is combined with doxycycline to treat the acute BSL-3 model of melioidosis, there is a 50% increase in survival compared with relevant controls. This benefit is not due to increasing the area under the concentration-time curve (AUC) of the antibiotic, suggesting the immunomodulatory nature of CD200-Fc treatment is playing an important role by potentially controlling the overactive immune response seen with many lethal bacterial infections. Traditional treatments for infectious disease have focused on the use of antimicrobial compounds (e.g. antibiotics) that target the infecting organism. However, timely diagnosis and administration of antibiotics remain crucial to ensure efficacy of these treatments especially for the highly virulent biothreat organisms. The need for early antibiotic treatment, combined with the increasing emergence of antibiotic resistant bacteria, means that new therapeutic strategies are required for organisms that cause rapid, acute infections. Here, we show that a layered defense approach, where an immunomodulatory compound is combined with an antibiotic, is better than an antibiotic combined with a relevant isotype control following infection with the biothreat agent . This approach has the potential to be truly broad spectrum and since the strategy includes manipulation of the host response it's application could be used in the treatment of a wide range of diseases.
抗菌药物耐药性仍然是一个全球性问题。病原体(如伯克霍尔德氏菌)已经进化出了排出某些抗生素并操纵宿主反应的机制。因此,需要新的治疗策略,例如分层防御方法。在这里,我们使用生物安全 2 级(BSL-2)和 BSL-3 鼠模型证明,将抗生素强力霉素与针对 CD200 轴的免疫调节药物联合使用,优于抗生素联合使用同种型对照的治疗方法。CD200-Fc 单独治疗可显著降低 BSL-2 和 BSL-3 模型中肺组织中的细菌负荷。当 CD200-Fc 治疗与强力霉素联合治疗急性 BSL-3 类鼻疽病模型时,与相关对照相比,存活率增加了 50%。这种益处不是由于增加抗生素的浓度-时间曲线下面积(AUC)引起的,这表明 CD200-Fc 治疗的免疫调节性质通过潜在地控制许多致死性细菌感染引起的过度活跃的免疫反应发挥着重要作用。 传染病的传统治疗方法侧重于使用针对感染生物体的抗菌化合物(例如抗生素)。然而,及时诊断和使用抗生素仍然是确保这些治疗方法有效性的关键,特别是对于高度致命的生物威胁生物体。早期抗生素治疗的需要,加上抗生素耐药细菌的不断出现,意味着需要针对引起快速、急性感染的生物体制定新的治疗策略。在这里,我们表明,分层防御方法,即免疫调节化合物与抗生素联合使用,优于抗生素与相关同种型对照联合使用,感染生物威胁剂后。这种方法有可能具有真正的广谱性,并且由于该策略包括对宿主反应的操纵,因此可以将其应用于治疗广泛的疾病。